MIRA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
1.2M
+4.8%
1.1M
-81.1%
5.8M
+342.3%
1.3M
-14.8%
1.5M
R&D
705.8K
+34.5%
524.8K
+5.7%
496.5K
+20.3%
412.6K
-16.8%
496.2K
SG&A
450.3K
-22.2%
578.7K
-89.1%
5.3M
+489.2%
904.3K
-13.9%
1.0M
Operating Income
-1156119
-4.8%
-1103479
+81.1%
-5824827
-342.3%
-1316985
+14.8%
-1546100
EBITDA
-1156119
-4.8%
-1103479
+81.1%
-5824827
-342.3%
-1316985
+14.8%
-1546100
Net Income
-1208534
-5.1%
-1150152
+80.8%
-5983321
-425.9%
-1137673
+26.0%
-1537712
EPS (Basic)
$-0.03
+0.0%
$-0.03
+78.6%
$-0.14
+88.1%
$-1.18
-1211.1%
$-0.09
EPS (Diluted)
$-0.03
+0.0%
$-0.03
+78.6%
$-0.14
+88.1%
$-1.18
-1211.1%
$-0.09
Shares (Diluted)
42.0M
+0.2%
41.9M
+0.2%
41.9M
+117.2%
19.3M
+13.5%
17.0M
MIRA Pharmaceuticals (MIRA) โ€” Financials